Session Information

  • WCLC 2021

    2021 World Conference on Lung Cancer

    Conference Program for 2021 the World Conference on Lung Cancer

    Presentation Date(s):  
    • September 8 - 14, 2021
    • Total Presentations: 1107

    All times listed are in Mountain Time MDT (UTC-6:00)

    PL - Plenary
    ES - Education Session
    OA - Oral Session
    MA - Mini Oral Session
    FP - Featured Posters
    P - Posters
    WS - Workshops
    IS - Industry Symposium
    MTE - Meet the Expert
    BEDG - Brain Exchange Discussion Groups

Filter Results:

Show Only CME Accredited Sessions

  • +

    P06 - Early Stage/Localized Disease/Ablative Therapies - Surgery

    • 00:00 - 00:00
    • 9/08/2021
    • Location: ePoster Hall
    • Not for CME Credit
    • Type: Posters
    • Track: Early Stage/Localized Disease/Ablative Therapies
    • +

      P06.04 - Clinical Outcomes and Pathological Characteristics of Resected ALK+ Lung Adenocarcinoma: A Single Center Retrospective Analysis

      00:00 - 00:00  |  Presenter: Zihua Zou

      • Abstract

      Loading...

  • +

    P40 - Multimodality of Advanced Lung Cancer - Clinical Outcomes

    • 00:00 - 00:00
    • 9/08/2021
    • Location: ePoster Hall
    • Not for CME Credit
    • Type: Posters
    • Track: Multimodality of Advanced Lung Cancer
    • +

      P40.01 - Maintenance Anlotinib After Induction Therapy With Platinum-Based Chemotherapy for Advanced Non-Small-Cell Lung Cancer: A Phase 2 Study

      00:00 - 00:00  |  Presenter: Yongqian Shu

      • Abstract

      Loading...

  • +

    P45 - Novel Therapeutics and Targeted Therapies - ALK/ROS1/MET

    • 00:00 - 00:00
    • 9/08/2021
    • Location: ePoster Hall
    • Not for CME Credit
    • Type: Posters
    • Track: Novel Therapeutics and Targeted Therapies
    • +

      P45.08 - Lorlatinib for Previously Treated ALK-Positive Advanced NSCLC: Primary Efficacy and Safety Data from a Phase 2 Study in China

      00:00 - 00:00  |  Presenter: Shun Lu

      • Abstract

      Loading...

  • +

    P51 - Novel Therapeutics and Targeted Therapies - EGFR Resistance

    • 00:00 - 00:00
    • 9/08/2021
    • Location: ePoster Hall
    • Not for CME Credit
    • Type: Posters
    • Track: Novel Therapeutics and Targeted Therapies
    • +

      P51.03 - Oritinib (SH-1028), a Third-generation EGFR-TKI in Advanced NSCLC Patients with Positive EGFR T790M: Results of a Single-arm Phase Ib Trial

      00:00 - 00:00  |  Presenter: Caicun Zhou

      • Abstract

      Loading...

  • +

    P64 - Small Cell Lung Cancer/ NET - Clinical Trial in Progress

    • 00:00 - 00:00
    • 9/08/2021
    • Location: ePoster Hall
    • Not for CME Credit
    • Type: Posters
    • Track: Small Cell Lung Cancer/ NET
    • +

      P64.02 - EMERGE 402 Phase 4 Observational Study: Safety and Outcomes in Patients With SCLC Receiving Treatment With Lurbinectedin

      00:00 - 00:00  |  Presenter: Raj Hanvesakul

      • Abstract

      Loading...

  • +

    OA06 - Prognosis and Staging

    • 08:15 - 09:15
    • 9/09/2021
    • Location: Program Auditorium
    • IASLC CME Accredited
    • Type: Oral
    • Track: Staging/Pulmonary Medicine
    • +

      OA06.01 - Validation of the 8th Ed TNM: Invasive Size for Pathologic T Descriptor in Stage I-IIA Resected Nonmucinous Adenocarcinomas

      08:15 - 08:25  |  Presenter: Yan Li

      • Abstract

      Loading...

  • +

    WS06 - Joint IASLC - CAALC - CSCO Workshop: Looking Toward the Future: Recognizing and Curing Lung Cancer

    • 22:15 - 23:45
    • 9/11/2021
    • Location: Program Auditorium
    • Not for CME Credit
    • Type: Workshop
    • Track: N.A.
    • +

      WS06.07 - Lorlatinib for Previously Treated ALK-Positive Advanced NSCLC: Primary Efficacy and Safety Data from a Phase 2 Study in China

      23:13 - 23:23  |  Presenter: Shun Lu

      • Abstract

      Loading...

  • +

    MA13 - Building on the Past: What Will Be the Next Immunotherapy Combination?

    • 17:30 - 18:30
    • 9/13/2021
    • Location: Program Auditorium
    • IASLC CME Accredited
    • Type: Mini Oral
    • Track: Immunotherapy (Phase II/III Trials)
    • +

      MA13.01 - Camrelizumab Plus Apatinib in Treatment-Naive Patients With Advanced Non-Squamous NSCLC: A Multicenter, Open-Label, Single-Arm, Phase 2 Trial

      17:30 - 17:35  |  Presenter: Shengxiang (Harry) Ren

      • Abstract

      Loading...